Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
Current Opinion in Endocrinology and Diabetes, 03/05/07
Rosenstock, Julio, et al. – Long term studies needed to confirm potential of glycemic control.
>Summary: The purpose of this research was to review recent clinical trials of oral dipeptidyl peptidase-4 inhibitors and examine their role in managing type 2 diabetes mellitus.
Outcomes: Oral dipeptidyl peptidase-4 inhibitors may prove valuable in the treatment of diabetes, given their effectiveness in reducing glycated hemoglobin with neutral weight effects and without the adverse events associated with other agents. Dipeptidyl peptidase-4 inhibitors appear to improve islet function and may modify the course of diabetes; this, however, must be confirmed with long-term controlled studies to demonstrate sustained glycemic control that translates into [beta]-cell preservation
| Previous Article | Next Article |
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review
Annals of Rheumatic Diseases, 06/09/09
Denosumab update
Current Opinion in Rheumatology, 06/11/09
Dapsone 5 Gel: A Review of its Efficacy and Safety in the Treatment of Acne Vulgaris
American Journal of Clinical Dermatology, 06/09/09
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Vascular Health and Risk Management, 05/11/09
A randomized trial of therapies for type 2 diabetes and coronary artery disease
New England Journal of Medicine, 06/10/09
Sponsor
Article Search
Sponsor


See Latest Articles


